Treatment with tolebrutinib led to greater confirmed disability improvement at 6 months compared with placebo in patients ...
Patients with relapsing MS treated with tolebrutinib vs teriflunomide had a clear reduction in disability accumulation with no difference in relapses.
No added benefits in slowing MS disability progression were found in a study that increased Ocrevus dosing to 2-3 times the ...
The study aimed to determine whether treatment with high dose ocrelizumab would provide an additional benefit in slowing disability progression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback